Background
Triple negative breast cancer (TNBC) is a very aggressive tumor for which no curative therapies currently exists [
1]. It accounts for around 15% of all breast tumors, and it is associated with poor prognosis, especially for patients with advanced disease, and a high grade of recurrence for those diagnosed in early stages [
1,
2]. In this context, identification of oncogenic vulnerabilities that could be pharmacologically inhibited is a main goal.
Among the novel agents that have shown preclinical activity are those targeting the bromo and extra terminal domain proteins (BET) [
3,
4], such as JQ1, currently in clinical development, which targets the BET protein BRD4. By inhibiting the acetylation of lysines of the tail of histones, BET inhibitors (BETi), such as the BRD4-targeting JQ1, reduce the expression of key oncogenic transcription factors, like DEP Domain Containing 1 (DEPDC), Forkhead box M1 (FOXM1), or LIM Domain Only 4 (LMO4), among others [
5,
6]. However, as for most therapies, it is expected that resistance to these agents will eventually appear after a prolonged time of treatment, decreasing the therapeutic efficacy of these compounds. Moreover, several mechanisms have been described to be implicated in the resistance to this family of compounds, including the presence of a stem cell phenotype, the activation of polo-like kinase 1 (PLK1), or the basal activity of intracellular signaling kinases like protein kinase B (AKT) or Cyclin-Dependent Kinase Activating Kinase (CSK1) [
7‐
12]. Reverting this resistance is crucial for BETi-based therapies to succeed.
Proteolysis targeting chimeric (PROTAC) molecules are a novel family of compounds with the ability to bind their target proteins and recruit an ubiquitin ligase, which promotes the targeted protein degradation [
13]. In the case of BRD4-targeting agents, like the BET-PROTAC MZ1, leading to degradation of the target via the proteasome [
14,
15]. This BET-PROTAC compounds have shown high activity in some hematological malignancies, like mantle lymphoma or acute myeloid leukemia (AML), compared with BETi [
16], but no particularly result has been reported in breast cancer. Similarly, no evaluation of efficacy of these compounds has been reported in BETi resistant cells.
In the present study we aimed to explore if BET-PROTACs were able to revert resistance to BET inhibitors in a breast cancer model of TNBC. In addition, we explored their mechanism of action in sensitive and resistant cells. Our results show that BET-PROTACs are very active in both cell models, and are able to diminish tumor growth in an in vivo model of mice xenografted with cells resistant to BETi.
Material and methods
Cell lines culture and drugs
TNBC and ovarian cell lines, MDA-MB-231 and BT549 and SKOV3, respectively, were cultured in DMEM, and ovarian cells OVCAR3 were cultured in RPMI supplemented with inactivated fetal bovine serum (10%), antibiotics (100 U/mL penicillin and 100 /mL streptomycin) and L-glutamine (2 mM) (Gibco (Thermofisher), Sigma-Aldrich) (37 °C, 5% CO2). All cell lines used were provided by Drs. J. Losada and A. Balmain, who purchased them from the ATCC, in 2015. Cells authenticity was confirmed by STR analysis at the molecular biology unit at the Salamanca University Hospital. MDA-MB-231-derived resistant cell line (MDA-MB-231R) was obtained by pulsed exposure to increasing doses of JQ1 (72 h pulses every 2 weeks for 6 months).
BET inhibitors (JQ1 (HPLC: 99.6% purity) and OTX-015 (HPLC: 99.82% purity) and PROTACs-BRD4 (MZ1 (HPLC: 99.5% purity) and ARV-825 (LCMS: 99.37% purity)), together with the inactive form of MZ1, cis-MZ1 (HPLC: 98.6% purity), were purchase from Selleckchem (Houston, TX) and Tocris Bioscience (Bio-Techne R&D Systems, S.LU).
For MTT assay colorimetric assay, after treatments, cell medium was replaced with MTT solution (red phenol-free DMEM with MTT 0.5 μg/μL) (45 min, 37 °C). DMSO was then used to solubilize the samples. Absorbance values were recorded in a multiwell plate reader (555 nm with a reference wavelength of 690 nm). For synergy studies, we used the Chou-Talalay algorithm, which allows to obtain the combination index (CI) to determined which combinations were synergistic (CI < 1), additive (CI = 1), or antagonic (CI > 1) using Calcusyn 2.0 software.
For clonogenic assays, 24 h-treated cells were counted and seeded in triplicates for each condition. After 10 days, cells were fixed with glutaraldehyde (0.5%, 15 min) and, then, stained with crystal violet (0.05%, 15 min). Colonies were quantified using Image J software. For 3D invasion assays, cells were seeded on 48-wells plates containing a 1 mm layer of Matrigel (Sigma-Aldrich) and treated for 72 h. Matrigel generates a net that mimics the extracellular matrix. Invading 3D structures were evaluated using an inverted microscope and their diameter was quantified using Image J software.
Flow cytometry experiments
For cell cycle analysis, after 12 h of treatment, cells were fixed in 70% ethanol in PBS (15 min). Cell pellets were washed in PBS + 2% BSA and incubated with Propidium iodide/RNAse staining solution (1 h, 4 °C, in dark; Immunostep).
For cell death studies, after 48 or 96 h of treatment, adherent and floating cells were collected and, after a wash with PBS, stained with Annexin Binding Buffer containing Annexin V-DT-634 and Propidium iodide (2 mg/mL) (1 h, RT, in dark; Immunostep). For caspase assays, cells were pre-treated with the pan-caspase inhibitor QVD (10 μM, 45 min; Sigma Aldrich) prior drug exposure.
All analyses were performed on a FACSCanto™ II flow cytometer using the FACS Diva software.
Protein expression analysis: Western-blotting
For the evaluation of protein levels, MDA-MB-231 and MDA-MB-231R cells were seeded (500.000 cell/100 mm dish) and, the following day, treated sequentially: first, the 48 h points; the following day, the 24 h points; and finally, the 12 h points. All treatments were collected in parallel 72 h post-seeding together with their common non-treated control.
For the evaluation of cell cycle and apoptosis-related proteins, cells were treated for 12 h and 96 h, respectively. Then cells were lysed, and protein extracts (25–60 μg) were used for Western blot analyses with the indicated antibodies (Additional file
2).
Caspase 3 activity
Caspase reaction buffer was added to the protein extract (50 μg, 1 h, 37 °C, in the dark). Then, fluorescence was measured (400/505 nm).
In vivo studies
BALB/c nu/nu mice (4–5 weeks old, n = 13) mammary fat pads were injected with MDA-MB-231R (2.5 × 106). Daily treatment with JQ1 (25 mg/kg, i.p.) was initiated when tumors reached a volume of 80–150 mm3. After 1 week of treatment with JQ1, a group of animals (n = 6) continued under this compound regime, while another group (n = 7) received a treatment of MZ1 (10 mg/kg, i.p.). Tumor growth was monitored for two more weeks. Then, tumors were collected, weighted, and stored at − 80 °C. For Western blot analysis, tumor samples (JQ1-treated n = 5; MZ1-treated n = 7) were homogenized with a sonicator Dispomix in ice-cold lysis buffer (1.5 mL/100 mg of sample). For protein levels evaluation, 60 μg of protein were used.
Statistical analysis
We used t-test for independent samples non-parametric assay, together with the Levenne test to consider, or not, equal variances or ANOVA assay with Tukey subtype. The level of significance was considered 95% (* p ≤ 0.05; ** p ≤ 0.01 and *** p ≤ 0.001). Software GraphPad Prism and SPSS were used.
Discussion
In the present article we describe the anti-tumor activity and the mechanism of action of BET-PROTACs MZ1 and ARV-25 in TNBC and ovarian cancer cell lines, and in a JQ1-resistant TNBC cell line (MDA-MB-231R). At the present moment, information about the mechanism of action of this family of compounds in relation to BETi is limited to lymphoma and acute myeloid leukemia [
16], and only limited data exists in solid tumors or in resistant models to BETi. Development of resistances is a relevant problem for all therapies after a prolonged treatment, and identification of agents that can act on that refractory population is a main objective with clear translation to the clinical setting.
In our study we observed a significant anti-tumoral activity of BET-PROTACs in TNBC and ovarian cancer, that was higher when compared to BETi that are currently in clinical development. This effect is observed using different approaches, including proliferation, invasion, and clonogenic assays. This data is in line with previous studies in AML and Lymphoma were these compounds showed potent lethality [
16,
18].
BET-PROTACs were able to efficiently deplete BRD4 and BRD2 in both sensitive and resistant cell lines, being MZ1 more potent than ARV-825. Of note, the JQ1 resistant cell line showed higher basal levels of BRD4 when compared with its naïve counterpart. This finding is in line with reports that suggest that treatment with BETi do not downregulate the expression of BRD4 [
18]. The efficient inhibition of BRD4 and BRD2 is translated to a significant induction of apoptosis in both sensitive and resistant cell lines. Notably, the mechanism mainly depended on caspases, as shown by the induction of caspase 3 and the inhibition of apoptosis observed upon treatment with a caspase inhibitor. In a similar manner, BET-PROTACs induced DNA damage, as measured by H2AX activation. Regarding the effect of these compounds on cell cycle, although BETi were able to induce arrest at G1, the effect of BET-PROTACs was more pleiotropic, showing a slight increase in G2/M. The increase expression of p21 and the reduction of cdc25c suggested an arrest at early G2 entry for both sensitive and resistant cells, results observed in other studies hematologic malignancies [
18].
In comparison with agents used in the current clinical setting, MZ1 showed a relevant anti-proliferative activity, and only docetaxel displayed higher efficacy. MZ1 high activity is probably the reason for the lack of synergisms observed when combining MZ1 with chemotherapies. A comparable effect was observed with the approved PARP inhibitor olaparib. BET-PROTACs have shown synergistic interactions with bcl-2 and CDK4/6 inhibitors in lymphoma probably through the activation of compensatory pathways [
16]. In addition, data suggest that PROTACS can revert resistant to current targeted therapies used in some hematological malignancies [
16,
19].
Finally, animal studies confirmed the effect of MZ1 on the proliferation of JQ1-resistant tumors. We first confirmed that JQ1 resistant cells were also resistant when injected in nude mice. Next, we observed that administration of MZ1 reduced growth of these tumors in vivo. Evaluation of the resected tumors showed a reduction of BRD4 in MZ1-treated animals, confirming that the effect was secondary to the reduction of this protein. Conversely, no reduction of BRD2 was identified in contrast to the findings observed in cell lines, probably due to a milder effect of the compound on this protein.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.